ARTICLE | Clinical News
Targretin: LGND will begin three Phase II/III pivotal trials over the next several months.
August 26, 1996 7:00 AM UTC
Ligand Pharmaceuticals Inc. (LGND), San Diego, Calif. Product: Targretin ( LGD1069) selective retinoid for the X receptor Indication: Cutaneous T cell lymphoma Status: LGND will begin three Phase II/...